High-dose 131I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan

Kayano, Daiki; Wakabayashi, Hiroshi; Nakajima, Kénichi; Kuroda, Rie; Watanabe, Satoru; Inaki, Anri; Toratani, Ayane; Akatani, Norihito; Yamase, Takafumi; Kunita, Yuji; Hiromasa, Tomo; Takata, Aki; Mori, Hiroshi; Saito, Shintaro; Araki, Raita; Taki, Junichi; Kinuya, Seigo

doi:10.1007/s12149-020-01460-z

Cited by 10 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advent of multidisciplinary treatment approaches (including chemotherapy, surgery, radiotherapy, and high‐dose chemotherapy with autologous peripheral blood stem cell rescue) has helped improve the prognosis of patients with neuroblastoma, with overall survival rates increasing from 29% (1990–1994) to 50% (2007–2010) 2 . However, persistence or relapse of neuroblastoma occurs in >50% of patients, and they have unfavorable prognosis with long‐term EFS of 40%–50% 3,4 despite the development of various salvage therapies, including irinotecan alone 5 ; irinotecan with temozolomide 6 ; ifosfamide, carboplatin, and etoposide (ICE) 7 ; topotecan and cyclophosphamide (TOPO‐CY) 8 ; and the high‐dose 131 I‐metaiodobenzylguanidine therapy 9 . In recent years, although the anti‐GD2 immunotherapy has become widely incorporated into the treatment of high‐risk neuroblastoma, the response rate in relapsed or refractory neuroblastoma is unsatisfactory even when combined with chemotherapy 10,11 .…”

Section: Introductionmentioning

confidence: 99%

“… 2 However, persistence or relapse of neuroblastoma occurs in >50% of patients, and they have unfavorable prognosis with long‐term EFS of 40%–50% 3 , 4 despite the development of various salvage therapies, including irinotecan alone 5 ; irinotecan with temozolomide 6 ; ifosfamide, carboplatin, and etoposide (ICE) 7 ; topotecan and cyclophosphamide (TOPO‐CY) 8 ; and the high‐dose 131 I‐metaiodobenzylguanidine therapy. 9 In recent years, although the anti‐GD2 immunotherapy has become widely incorporated into the treatment of high‐risk neuroblastoma, the response rate in relapsed or refractory neuroblastoma is unsatisfactory even when combined with chemotherapy. 10 , 11 Therefore, the development of new chemotherapeutic regimens is still imperative for patients with relapsed or refractory neuroblastoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Management of relapse requires aggressive therapies including radionuclide treatments that are often limited because of associated toxicities. Several recent clinical studies used either high-dose or peptide-modified MIBG-based therapies (Kayano et al 2020 ; Sugiyama et al 2020 ). Despite some promising findings of these studies, development of more efficient treatments that work on most neuroblastoma phenotypes and for refractory disease is critically important.…”

Section: Discussionmentioning

confidence: 99%

“…MIBG has been shown to accumulate in nearly 85–90% of neuroblastoma through their expression of adrenaline/norepinephrine transporters (Carlin et al 2003 ). Radioactive 131 I-MIBG is currently used for diagnosis (Paltiel et al 1994 ) as well as the treatment of high-risk and refractory neuroblastoma (Kayano et al 2020 ; Matthay et al 2007 ; Sugiyama et al 2020 ). In this study, we confirmed previous assessment that MIBG may accumulate in mitochondria (Gaze et al 1991 ) as well as cytosol (Additional file 1 : Figures S3 and S4).…”

Section: Discussionmentioning

confidence: 99%

Development of Fe3O4 core–TiO2 shell nanocomposites and nanoconjugates as a foundation for neuroblastoma radiosensitization

et al. 2021

View full text Add to dashboard Cite

Background Neuroblastoma is the most common extracranial solid malignancy in childhood which, despite the current progress in radiotherapy and chemotherapy protocols, still has a high mortality rate in high risk tumors. Nanomedicine offers exciting and unexploited opportunities to overcome the shortcomings of conventional medicine. The photocatalytic properties of Fe3O4 core-TiO2 shell nanocomposites and their potential for cell specific targeting suggest that nanoconstructs produced using Fe3O4 core-TiO2 shell nanocomposites could be used to enhance radiation effects in neuroblastoma. In this study, we evaluated bare, metaiodobenzylguanidine (MIBG) and 3,4-Dihydroxyphenylacetic acid (DOPAC) coated Fe3O4@TiO2 as potential radiosensitizers for neuroblastoma in vitro. Results The uptake of bare and MIBG coated nanocomposites modestly sensitized neuroblastoma cells to ionizing radiation. Conversely, cells exposed to DOPAC coated nanocomposites exhibited a five-fold enhanced sensitivity to radiation, increased numbers of radiation induced DNA double-strand breaks, and apoptotic cell death. The addition of a peptide mimic of the epidermal growth factor (EGF) to nanoconjugates coated with MIBG altered their intracellular distribution. Cryo X-ray fluorescence microscopy tomography of frozen hydrated cells treated with these nanoconjugates revealed cytoplasmic as well as nuclear distribution of the nanoconstructs. Conclusions The intracellular distribution pattern of different nanoconjugates used in this study was different for different nanoconjugate surface molecules. Cells exposed to DOPAC covered nanoconjugates showed the smallest nanoconjugate uptake, with the most prominent pattern of large intracellular aggregates. Interestingly, cells treated with this nanoconjugate also showed the most pronounced radiosensitization effect in combination with the external beam x-ray irradiation. Further studies are necessary to evaluate mechanistic basis for this increased radiosensitization effect. Preliminary studies with the nanoparticles carrying an EGF mimicking peptide showed that this approach to targeting could perhaps be combined with a different approach to radiosensitization – use of nanoconjugates in combination with the radioactive iodine. Much additional work will be necessary in order to evaluate possible benefits of targeted nanoconjugates carrying radionuclides. Graphic abstract

show abstract

“…High dose 131 I-MIBG targeted therapy has been applied recently in Japan to treat children with relapsed neuroblastoma, who were administered with treatment ranging from 444 to 666 MBq/kg. The children achieved an event-free survival and overall survival rates at 1-year post-therapy of 42% and 58%, respectively, without significant hematological toxicity [16].…”

Section: Metaiodobenzylguanidine (Mibg)mentioning

confidence: 91%

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors

Cimini

Ricci

Chiaravalloti

et al. 2020

IJMS

View full text Add to dashboard Cite

The use of theragnostic radiopharmaceuticals in nuclear medicine has grown rapidly over the years to combine the diagnosis and therapy of tumors. In this review, we performed web-based and desktop literature research to investigate and explain the potential role of theragnostic imaging in pediatric oncology. We focused primarily on patients with aggressive malignancies such as neuroblastoma and brain tumors, to select patients with the highest chance of benefit from personalized therapy. Moreover, the most critical and groundbreaking applications of radioimmunotherapy in children’s oncology were examined in this peculiar context. Preliminary results showed the potential feasibility of theragnostic imaging and radioimmunotherapy in pediatric oncology. They revealed advantages in the management of the disease, thereby allowing an intra-personal approach and adding new weapons to conventional therapies.

show abstract

High-dose 131I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan

Cited by 10 publications

References 22 publications

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma

Development of Fe3O4 core–TiO2 shell nanocomposites and nanoconjugates as a foundation for neuroblastoma radiosensitization

Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors

Contact Info

Product

Resources

About